00:00The promise of nanospresso across the globe, millions suffer in silence.
00:05They battle what are known as orphan diseases,
00:09conditions so rare that pharmaceutical companies often see little commercial incentive to develop treatments.
00:15Enter nanomedicine, a field working at an incredibly tiny scale.
00:20Within this realm, nucleic acid therapeutics like messenger RNA or DNA offer an unprecedented level of precision.
00:27Think of them as genetic instructions, capable of correcting or silencing the faulty proteins that cause so many diseases.
00:36They are the master keys designed for specific locks within our cells.
00:41Nucleic acid therapeutics offer highly specific solutions by targeting the protein abnormalities at the root of many conditions,
00:49including rare diseases and cancer.
00:51Nucleic acids, despite variations in sequence, share a fundamental molecular similarity.
00:58Making them ideal for platform-based production in local hospital pharmacies.
01:03This allows for unique, patient-specific treatments to be created precisely where care is administered,
01:09including a wide range of neurodegenerative conditions caused by genetic anomalies or protein dysregulation.
01:16This flexibility isn't limited to orphan diseases.
01:19It could extend to personalized oncology and combating emerging pathogens.
01:25Finally, democratizing access.
01:29The nanospresso model combines nucleic acid therapeutics with these nanomedicine delivery platforms
01:34to offer a new paradigm of rapid personalized therapies produced at the point of care.
01:39Imagine a high-tech coffee machine, but instead of coffee, it uses genetic instructions.
01:45Instead of milk, it uses protective lipid nanoparticles.
01:50With this machine, a hospital pharmacist can instantly and personally brew a nanomedicine espresso for each patient,
01:57delivering the precise instructions their body needs.
02:00This is a stark contrast to large factories, mass-producing a single blend.
02:05This way, even those with a very rare taste.
02:09An orphan disease can have their custom-made coffee, fresh and available exactly when and where they need it.
02:16This not only enhances accessibility for rare disease patients, but could also benefit low-income regions.
02:23They also enable adaptable vaccines, as seen with COVID-19 variants.
02:30Second, addressing current challenges.
02:33Despite their potential, these treatments have been hampered by high costs.
02:37Complex manufacturing, a lack of commercial incentives for rare diseases,
02:42and difficult approval and reimbursement processes.
02:45It's like having an incredible race car, but with an exorbitant price tag and few gas stations.
02:50Individually, these diseases affect few, but collectively, the patient count is staggering.
02:58In the European Union alone, 36 million people live with a rare disease,
03:03often with no treatment options available,
03:05though specific applications for neurodegenerative diseases aren't detailed.
03:10The underlying technology has immense potential here.
03:13For example, it's been used to silence pathogenic protein production in conditions like hereditary transthyrotin amyloidosis,
03:21which can have neurological manifestations.
03:24The approved drug Patesian already uses LNPs to deliver a small, interfering RNA for this condition.
03:31Furthermore, antisense oligonucleotides, another type of therapeutic nucleic acid,
03:36are being developed for hereditary neurodegenerative diseases.
03:42This grim reality is driven by astronomical development costs,
03:46complex manufacturing, and stringent regulatory hurdles.
03:50But what if we could flip the script?
03:53What if we could make highly specific, life-changing treatments readily available even for the rarest conditions?
03:59The challenge?
04:00These powerful molecules are large, negatively charged, and incredibly fragile.
04:06Getting them past our cells-protective, almost impermeable membranes has been a formidable barrier.
04:12This is where Nanespresso steps in,
04:14a project whose very name evokes the convenience of a home-brewed coffee,
04:19its mission to democratize access to personalized treatments for rare diseases and other conditions,
04:25making them both available and affordable for healthcare systems worldwide.
04:31Nanespresso proposes a paradigm shift,
04:34decentralizing the production of nucleic acid-based nanomedicines.
04:38Instead of vast, centralized factories,
04:41the Nanespresso model empowers hospital pharmacists
04:44to assemble custom treatments directly within the hospital,
04:47even at the patient's bedside.
04:50How?
04:51By seamlessly integrating advanced microfluidics.
04:54Technology that precisely mixes liquids in tiny channels,
04:59with lipid nanoparticle engineering platforms.
05:03These LNPs are minuscule fatty capsules that encase nucleic acids,
05:08shielding them and facilitating their entry into cells.
05:11Their effectiveness was dramatically proven with the success of Mr. N.A. COVID-19 vaccines.
05:17This approach is a modern twist on the ancient art of compounding.
05:20For pharmacists prepared tailor-made medicines for individual patients,
05:25now powered by cutting-edge technology,
05:28Nanespresso focuses on four key pillars.
05:32First, high-precision treatments.
05:34Third, personalized production in the hospital.
05:37While the article highlights orphan diseases,
05:40many neurodegenerative conditions fall into this category.
05:43Often stemming from genetic bases that cause protein issues in the brain or nervous system.
05:50Given Nanespresso's versatility in producing custom nucleic acid nanomedicines,
05:55its ability to create personalized treatments at the point of care
05:58could significantly accelerate access to these therapies.
06:02In essence, the Nanespresso platform could be the crucial link bringing innovative genetic and RNA.
06:08Therapies to patients with neurodegenerative diseases who currently lack treatment options
06:14due to their rarity or complexity.
06:17Money Explainers
Comentarios